Definium Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 World Trade Ctr Ste 8500, New York, Ne...Phone Number
(212) 220-6633Website
www.definiumtx.comRevenue
-Stock Symbol
DFTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Definium Therapeutics
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.Explore more
Definium Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Definium Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Definium Therapeutics is spiking on competitors!
Check if Definium Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Definium Therapeutics
Funding: Get notified immidiatlly once Definium Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Definium Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Definium Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Definium Therapeutics recently announced quarterly report
Product Launch: Get notified when Definium Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Definium Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Definium Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Definium Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Definium Therapeutics.
Definium Therapeutics financials insights
Gather financial insights about Definium Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$700M
Definium Therapeutics Tech Stack
A closer look at the technologies used by Definium Therapeutics
Most Recent Scoops
Earnings
Definium Therapeutics has reported a net loss of $159 million for Q2 2026, compared to $42.7 million for Q2 2025, with the increase significantly impacted by an $86.2 million non-cash expense resulting from the change in fair value of the company's 2022 USD financing warrants, which are marked to market each quarter and reflected the rise in share price from $18.90 at March 31, 2026 to $47.04 at June 30, 2026.
Earnings, Business Finance, Finance
Open Position
Open Position
Open Position
Project
Medical Research, Pharmaceuticals, Clinical Operations
Definium Therapeutics News & Media
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder August 12, 2026 8:00 AM...A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) Issued on behalf of Helus Pharma (Nasdaq: HELP)Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120
Definium Therapeutics (NasdaqGS:DFTX) reported positive topline Phase 3 results for DT120 in major depressive disorder. The company completed a US$700 million follow on equity offering to fund regulatory and commercialization plans for DT120. The latest data readout and capital raise were announced together as Definium Therapeutics positions DT120 for potential market entry. Definium Therapeutics focuses on treatments for psychiatric conditions, with DT120 targeting major depressive...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Definium Therapeutics
Sign Up For FreeTo access detailed company insights
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methyl... Read More
